#United States #Becton Dickinson #Babson Diagnostics #Blood Testing #Franklin Lakes and Austin

BD and Babson Diagnostics Introduce Fingertip Blood Testing

In a significant advancement in healthcare technology, BD (Becton, Dickinson and Company) and Babson Diagnostics have recently launched an innovative fingertip blood collection and testing system. This initiative aims to enhance healthcare delivery within U.S. health systems and provider networks, specifically in settings such as urgent care facilities and family doctors' offices.

Making Blood Testing Easier and Less Invasive

This state-of-the-art blood testing method merges BD’s MiniDraw™ Capillary Blood Collection System with Babson’s proprietary BetterWay technologies. The result is a groundbreaking procedure that only requires a minimal amount of blood—tested from just six drops collected from a finger prick. This less invasive alternative to traditional venipuncture not only simplifies the process but also allows any trained healthcare worker, even those lacking phlebotomy experience, to collect and prepare the samples.

According to industry insights, 70% of clinical decisions are informed by diagnostic test results. Blood tests are a primary component of patient care, enabling healthcare providers to diagnose, monitor, and treat various conditions efficiently. The new fingertip blood collection system is particularly beneficial for patients in underserved areas lacking access to trained phlebotomy professionals, as it helps minimize the challenges often associated with blood testing, including fears related to needles.

Bridget Bagnato, the Worldwide President of Specimen Management at BD, emphasized the importance of this advancement: "In many parts of the United States, patients experience significant delays in receiving necessary blood draws due to service shortages. By streamlining this common procedure, we can not only make blood testing more convenient but also boost patient satisfaction and health outcomes."

A Collaborative Effort for Innovation

This venture is an extension of the collaboration that BD and Babson Diagnostics began back in 2016, reflecting a commitment to enhance capillary blood testing technology. David Stein, CEO of Babson Diagnostics, stated, "BD has a 75-year history of innovation in blood collection technology. We believe that our partnership will lead to transformative solutions that enhance patient-centered healthcare delivery."

The BetterWay blood testing system has already made its presence felt in retail environments since May 2024, providing more accessible blood testing options in locales such as neighborhood pharmacies. The recent expansion of this service aims to bring these capabilities to patients in various ambulatory care sites nationwide.

About BD and Babson Diagnostics

BD stands out as one of the world’s premier medical technology companies, dedicated to pushing the frontiers of healthcare through advancements in diagnostics and care delivery. With over 70,000 employees globally, BD is committed to enhancing the safety and efficiency of healthcare provision. For more information about their offerings, visit bd.com.

On the other hand, Babson Diagnostics is transforming the landscape of blood testing through its science-driven solutions, designed to make testing more patient-friendly. Their BetterWay system aids healthcare organizations in attracting new patients, improving health equity, and lowering costs by introducing efficient testing processes across various care settings. To learn more about their initiatives, visit betterway.com.

Given the increasing need for innovative solutions in healthcare, the BD and Babson partnership heralds a new era in patient diagnostics and care, setting the stage for a more efficient healthcare system that prioritizes accessibility and patient satisfaction.